A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
ACP-204-013
Phase 3 other active
Quick answer
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) for Lewy body Dementia psychosis (LBDP) is a Phase 3 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Lewy body Dementia psychosis (LBDP)
- Phase
- Phase 3
- Modality
- other
- Status
- active